Brivaracetam And Levetiracetam In Clinical Practice: Assessment Of Safety And Effectiveness Using An Observational Study Design
International Journal of Drug Delivery Technology · 11.05.2026 · 16 (26s)
DOI: 10.25258/ijddt.16.26s.82 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 11.05.2026. Verfasst von Martina Jenifer M und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Plan: The present study aims to provide an overview of the data about the relative clinical safety and effectiveness of levetiracetam (LEV) and brivaracetam (BRV) in treating epileptic patients. Preface: Epilepsy is a chronic non-communicable disease of the brain characterized by recurrent seizures. Levetiracetam is a second-generation antiepileptic drug, and Brivaracetam is a new third-generation drug in the pyrrolidine class of anticonvulsants and an analogue of LEV. The prospective observational study was conducted in the Neurology department of a tertiary care multi-speciality hospital in Coimbatore between the period of 2024 and 2025. Written informed consent from each patient or the patient’s caregiver was obtained for conducting the study. Safety and efficacy data were collected during patients’ visits and follow-up. The population will be screened based on inclusion criteria, which include patients with epilepsy aged 16 years or older with current and previous mental health conditions, and exclusion criteria, which exclude patients with a history of alcoholism or drug abuse.
Method
In this study, 116 patients were evaluated, ranging in age from adolescents to older adults, and the majority were between 16 and 29 (44%). The study observed that the incidence of epilepsy is highly agedependent. Children are at higher risk than other age groups, and it remains prevalent in old age. The risk in children is often due to genetic causes, malformations of cerebral development and hypoxic-ischemic encephalopathy. Observation found that the male patient population (58%) was higher than the female population (42%). Outcome: An indirect treatment comparison found no statistically significant differences between levetiracetam and brivaracetam in terms of safety and adverse events (AE). Behavioural adverse events (BAE) appear to be less prevalent with brivaracetam than with levetiracetam. The most common TEAEs reported in patients receiving levetiracetam were headache, and in patients receiving brivaracetam were dizziness. Levetiracetam monotherapy was associated with significantly higher odds of experiencing a greater number of seizure episodes compared with brivaracetam monotherapy, and levetiracetam used in combination with other antiepileptic drugs showed significantly higher efficacy.
Conclusion
Results from the study indicate that both drugs have similar safety and tolerability in the epileptic population, and efficacy analyses showed seizure reduction and seizure frequency are comparatively better with the brivaracetam group over time.
Zitieren
APA
M, M. J., Andhuvan, G., Vedhanayagam, N., Sriram, S., H, A. M., & Divakar, M. C. (2026). Brivaracetam And Levetiracetam In Clinical Practice: Assessment Of Safety And Effectiveness Using An Observational Study Design. International Journal of Drug Delivery Technology, 16(26s). https://doi.org/10.25258/ijddt.16.26s.82
Vancouver
M MJ, Andhuvan G, Vedhanayagam N, Sriram S, H AM, Divakar MC. Brivaracetam And Levetiracetam In Clinical Practice: Assessment Of Safety And Effectiveness Using An Observational Study Design. International Journal of Drug Delivery Technology. 2026;16(26s). doi:10.25258/ijddt.16.26s.82
BibTeX
@article{M2026,
author = {M, Martina Jenifer and Andhuvan, G and Vedhanayagam, N and Sriram, S and H, Afrith Mohamed and Divakar, Madhu C},
title = {Brivaracetam And Levetiracetam In Clinical Practice: Assessment Of Safety And Effectiveness Using An Observational Study Design},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {26s},
doi = {10.25258/ijddt.16.26s.82}
}
EUVIMED